Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HT61 1% gel versus vehicle and mupirocin for nasal Staphylococcus aureus decolonisation
2009-017398-39Phase 3Terminated
- Sponsor
- Helperby Therapeutics
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HT61 in Staphylococcus aureus nasal carriage and nasal carriage of methicillin-resistant Staphylococcus aureus (4 arms), sponsored by Helperby Therapeutics. Primary endpoints: Nasal decolonisation with HT61 vs vehicle and Nasal decolonisation with HT61 vs mupirocin. Started Mar 2010; status: terminated.
02
Drugs
HT61
03
Conditions
Staphylococcus aureus nasal carriagenasal carriage of methicillin-resistant Staphylococcus aureus
Beyond the preview
Go deeper on 2009-017398-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017398-39.